Gene by Gene’s Post

Right drug, right patient, right dose. Safe care is healthcare.

In this enlightening video, we delve into Gamma Delta T Cell Therapy for cervical cancer, unlocking the secrets behind this innovative treatment. Discover how this therapy is revolutionizing the fight against cervical cancer and providing new hope for patients. Join us as we explore the science, success stories, and future potential of Gamma Delta T Cell Therapy in transforming cancer care. #GammaDeltaTCells #CervicalCancer #CancerTreatment #MedicalInnovation #Healthcare #PatientHope #CancerResearch #BreakthroughTherapy #Oncology #HealingJourney Services provided by CancerFax to cancer patients: 1) CAR T-Cell therapy in China 2) Cancer clinical trials recruitment 3) CAR T Cell therapy 4) Gene therapy for genetic disorders 5) TIL therapy for cancer treatment 6) NK Cell therapy Empowering Lives, Transforming Journeys: Our vision is to lead the way in revolutionizing cancer treatment facilitation, ensuring every individual's access to personalized, comprehensive, and compassionate care. Through innovative solutions and unwavering dedication, we strive to eliminate barriers, provide hope, and contribute to a world where cancer is not just treatable, but conquerable. +14243816660☎️

Combining genomic analyses with information about clinical outcomes is a highly promising strategy to understanding prostate cancer and its treatment.

Are you up to date on the latest advancements in TIL therapy? Our newest blog post delves into how Tumor-Infiltrating Lymphocytes (TIL) therapy is transforming cancer treatment by harnessing the power of the body's immune cells. Featuring insights from Dr. Raj Puri and a powerful patient story from Chris White. Read the highlights in our blog: https://hubs.ly/Q02Lzbzn0 #CancerResearch #TILTherapy #LifeSciences #BridgingTheGap

Friends of Cancer Research Policy & Regulatory Initiatives bring together stakeholders to assess emerging challenges in oncology drug development to inform policy recommendations for modernizing regulatory frameworks and clinical trials.   Some examples of Policy & Regulatory Initiatives: Cell & Gene Therapies: Our cell and gene therapies (CGT) work enhances the translation of evidence to support clinical development and adoption of these therapies.  By supporting alignment, we can ensure these innovative therapies reach patients safely and quickly.    Clinical Trial Eligibility Criteria: Overly restrictive eligibility criteria limit patient access to potentially life-saving treatments and can impede progress. We partnered with the American Society of Clinical Oncology (ASCO) to develop recommendations for broadening eligibility criteria used in cancer clinical trials to enhance trial results, reduce health disparities, and improve outcomes for patients.  Tolerability & Dosing: As targeted therapies have emerged and are used for longer periods of time, understanding the tolerability of a therapy is critical to inform the optimal dose. We work to ensure oncology #clinicaltrials include patient-centered approaches to dosage optimization to support an understanding of tolerability.  Find out what other policy initiatives we’re working on:   https://lnkd.in/ep7EyQv2  

I'm excited to share our latest article on a rapidly emerging and important subtype of breast cancer: HER2-low Breast Cancer (BC) 💡🦀 In this review, we dive into the distinct clinical and molecular characteristics of HER2-low BC, a subtype defined by its low level of HER2 protein expression. Unlike the more aggressive HER2-positive BC, HER2-low BC often presents a more favorable prognosis, with early studies suggesting it is less likely to metastasize and may respond well to standard treatments like chemotherapy, radiation, and hormone therapy. However, there's still much to learn! Our article highlights ongoing research efforts aimed at uncovering the genetic mutations driving HER2-low BC and developing targeted therapies to improve patient outcomes. 🔍 Key Takeaways: 🔬 HER2-low BC's unique profile compared to other BC subtypes. 📉 Potentially better prognosis and responsiveness to standard treatments. 🧬 The need for further research to develop targeted interventions. #BreastCancer 🎗️ #CancerResearch 🔬 #HER2Low 🧬 #Oncology 🏥 #MedicalResearch 📚 #HealthcareInnovation 💡 #NewPublication 📝

Bizengri (zenocutuzumab) - Mechanism of Action https://lnkd.in/eNPWaMaW On December 4, 2024, the FDA granted accelerated approval to Bizengri (zenocutuzumab-zbco) for patients with the following: 1- advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. 2- advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a NRG1 gene fusion with disease progression on or after prior systemic therapy. This represents the first FDA approval of a systemic therapy for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion. Bizengri Prescribing Information https://lnkd.in/eVwUcRgT The recommended zenocutuzumab dose is 750 mg, as an intravenous infusion every 2 weeks, until disease progression or unacceptable toxicity. #Cancer #Oncology #NRG1 #Bizengri #zenocutuzumab #LungCancer #NonSmallCellLungCancer #NSCLC #PancreaticCancer #PancreaticAdenocarcinoma #Moffitt #MoffittCancerCenter Moffitt Cancer Center

Combining genomic analyses with information about clinical outcomes is a highly promising strategy to understanding prostate cancer and its treatment.

Open Exploration | Exploration of Targeted Anti-tumor Therapy 📚 Popular New Cited #Review sharing! Happy reading! 📄 Titled "DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, #prognosis and #PrecisionMedicine". 👨🏫 This insightful piece by Weifeng Ding * et al. 🔖 This review compiles a comprehensive body of evidence underscoring the significant involvement of DNA methylation modifications in the pathogenesis of CRC. Moreover, this review explores the potential utility of DNA methylation in cancer diagnosis, prognostics, assessment of disease activity, and prediction of drug responses. 🗺️ This article belongs to the special issue #CancerEpigenetics: Implications for Novel Therapeutic Strategies 📍 Access the full text at: https://lnkd.in/g7RmMvEb 💯 Don't miss out on this exciting opportunity to expand your knowledge and stay up-to-date with the latest developments. ❗ Happy reading! #EpigeneticModification, #DNAMethylation, #ColorectalCancer, #Diagnosis, #MetabolismReprogramming

Do you know what it takes to successfully design hereditary cancer panels? Labs like Ambry must balance gene-disease validity, clinical guidelines, evolving clinician preferences and payor considerations to ensure healthcare providers get the most out of our tests, which is why we put so much thought into enhancements to our heredity cancer testing menu. Read more: https://hubs.ly/Q02YmFQW0 Carolyn Horton #NSGCPerspectives